aplastic anemia | Page 2 | Aplastic Anemia and MDS International Foundation

aplastic anemia

Kansas City

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
Event Date: 
Sat, 10/14/2017 -
7:30am to 1:30pm
Conference Event Type: 

Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

Author(s): 
Zhao X, Feng X, Wu Z, Winkler T, Desmond R, Olnes M, Dumitriu B, Townsley DM, Dunbar CE, Young NS
Primary Author: 
Zhao X
Journal Title: 
Exp Hematol
Original Publication Date: 
Sep 2017

Although hematopoietic growth factors are at high levels in

Bone Marrow Diseases: 

Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia

Author(s): 
Atta EH, Lima CBL, Dias DSP, Clé DV, Bonduel MM, Sciuccati GB, Medeiros LA, Oliveira MM, Salvino MA, Garanito MP, Blum Fonseca PB, Saad STO, Calado RT, Scheinberg P
Primary Author: 
Atta EH
Journal Title: 
Ann Hematol
Original Publication Date: 
Aug 2017

Despite being recommended as first-line immunosuppressive therapy in severe

Bone Marrow Diseases: 

Nivolumab-induced aplastic anemia: A case report and literature review

Author(s): 
Comito RR, Badu LA, Forcello N
Primary Author: 
Comito RR
Journal Title: 
J Oncol Pharm Pract
Original Publication Date: 
Aug 2017

Directed immunotherapy at the programmed cell death-1 receptor has demonstrated efficacy in non-small-cell lung cancer, metastatic melanoma, and various other malignancies. Immune checkpoint inhibitors are innovative therapies producing some impressive clinical responses with a more manageable adverse effect profile when compared to traditional

Bone Marrow Diseases: 

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

Author(s): 
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T
Primary Author: 
Boddu P
Journal Title: 
Am J Hematol
Original Publication Date: 
Aug 2017

Newer treatment modalities are being investigated to improve upon historical outcomes with standard immunosuppressive therapy (IST) in

Bone Marrow Diseases: 

Newark

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.
Event Date: 
Sat, 09/16/2017 -
8:00am to 3:30pm
Conference Event Type: